nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT01365169,"""CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial""",Not Applicable,Recruiting,Interventional,Malignant Head and Neck Neoplasm; Malignant Neoplasm; Metastatic Malignant Neoplasm in the Neck; Metastatic Malignant Neoplasm in the Uterine Cervix; Pancreatic Adenocarcinoma; Pancreatic Neuroendocrine Carcinoma; Recurrent Colorectal Carcinoma; Stage I Colorectal Cancer AJCC v6 and v7; Stage I Hypopharyngeal Carcinoma AJCC v7; Stage I Major Salivary Gland Cancer AJCC v7; Stage I Nasopharyngeal Carcinoma AJCC v7; Stage I Oral Cavity Cancer AJCC v6 and v7; Stage I Oropharyngeal Carcinoma AJCC v6 and v7; Stage II Colorectal Cancer AJCC v7; Stage II Hypopharyngeal Carcinoma AJCC v6 and v7; Stage II Major Salivary Gland Cancer AJCC v7; Stage II Nasopharyngeal Carcinoma AJCC v7; Stage II Oral Cavity Cancer AJCC v6 and v7; Stage II Oropharyngeal Carcinoma AJCC v6 and v7; Stage IIA Colorectal Cancer AJCC v7; Stage IIB Colorectal Cancer AJCC v7; Stage IIC Colorectal Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Hypopharyngeal Carcinoma AJCC v7; Stage III Laryngeal Cancer AJCC v6 and v7; Stage III Major Salivary Gland Cancer AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Oral Cavity Cancer AJCC v6 and v7; Stage III Oropharyngeal Carcinoma AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Hypopharyngeal Carcinoma AJCC v7; Stage IVA Laryngeal Cancer AJCC v7; Stage IVA Major Salivary Gland Cancer AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVA Oral Cavity Cancer AJCC v6 and v7; Stage IVA Oropharyngeal Carcinoma AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Hypopharyngeal Carcinoma AJCC v7; Stage IVB Laryngeal Cancer AJCC v7; Stage IVB Major Salivary Gland Cancer AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVB Oral Cavity Cancer AJCC v6 and v7; Stage IVB Oropharyngeal Carcinoma AJCC v7; Metastatic or Locally Unresectable Solid Tumor,Exercise Intervention; Health Telemonitoring; Health Telemonitoring; Health Telemonitoring; Health Telemonitoring; Health Telemonitoring; Quality-of-Life Assessment; Questionnaire Administration; Health Telemonitoring,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),590,2011-05-25,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT01365169
NCT02333604,Cancer Experience Registry: An Online Survey Research Study to Understand the Experiences of Cancer Patients and Caregivers,,Recruiting,Observational,Neoplasms; Cancer; Caregiver,,,"Cancer Support Community, Research and Training Institute, Philadelphia",,15000,2013-03-05,2035-12-05,United States,No,https://clinicaltrials.gov/study/NCT02333604
NCT02775461,Pancreas Disease and High Risk Registry,,Recruiting,Observational,Pancreas Cancer; Pancreatitis; Chronic Pancreatitis; Pancreatic Cyst; Family History of Pancreas Cancer; Genetic Mutations,,,Icahn School of Medicine at Mount Sinai,,1116,2013-03-01,2033-11-05,United States,No,https://clinicaltrials.gov/study/NCT02775461
NCT03260491,"A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC),HER3-DXd (FL-DP); HER3-DXd (CTM-1 Lyo-DP); HER3-DXd (CTM-3 Lyo-DP),,Daiichi Sankyo,Merck Sharp & Dohme LLC,309,2017-10-30,2026-12-31,Japan; Netherlands; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT03260491
NCT04130516,"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult","LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody",,"Linnaeus Therapeutics, Inc.",Merck Sharp & Dohme LLC,200,2019-10-21,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT04130516
NCT04220905,Large Polyp Study (LPS) III - Endoscopic Resection of Large Colorectal Polyps: An Observational Cohort Study,,Recruiting,Observational,Colonic Polyp; Colonoscopy; Complication; Recurrence; Duodenal Polyp,,,White River Junction Veterans Affairs Medical Center,,1500,2017-11-01,2025-05-05,United States,No,https://clinicaltrials.gov/study/NCT04220905
NCT04291105,Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors,Phase 2,Recruiting,Interventional,Melanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Cancer,VV1; Cemiplimab,,"Vyriad, Inc.",Regeneron Pharmaceuticals,87,2020-04-24,2025-12-05,Brazil; United States,No,https://clinicaltrials.gov/study/NCT04291105
NCT04302025,"NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,Alectinib; Entrectinib; Vemurafenib; Cobimetinib; Pralsetinib; Atezolizumab; SBRT; Resection; Chemotherapy; Divarasib,,"Genentech, Inc.",,99,2020-11-06,2030-05-30,United States,No,https://clinicaltrials.gov/study/NCT04302025
NCT04373564,Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group,Phase 4,Recruiting,Interventional,Motor Function; Cognitive Function; Contrast Media,Motor Tests; Cognitive Tests; Unenhanced-MRI of the brain; Gadolinium Measurements; Gadoxetate disodium; Gadobenate dimeglumine; Gadodiamide; Gadoterate meglumine; Gadobutrol; Gadoteridol,,Guerbet,Bayer AG (Sponsor); Bracco (Sponsor); GEHC (Sponsor),2076,2021-03-24,2028-12-31,Brazil; Canada; France; Germany; Italy; Russia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04373564
NCT04421820,A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours,Phase 1/Phase 2,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma,BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion); BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation),,"Bold Therapeutics, Inc.",,220,2020-08-28,2026-09-01,Canada; Ireland; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04421820
NCT04511039,A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers,Phase 1,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Clinical Stage III Gastroesophageal Junction Adenocarcinoma; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A; Locally Advanced Colorectal Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Trifluridine and Tipiracil Hydrochloride; Talazoparib Tosylate,,Roswell Park Cancer Institute,Pfizer; National Cancer Institute (NCI),45,2021-06-08,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT04511039
NCT04589845,Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,Phase 2,Recruiting,Interventional,Solid Tumors,Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib,,Hoffmann-La Roche,,920,2021-01-18,2032-09-25,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Israel; Italy; Japan; New Zealand; Poland; Portugal; Puerto Rico; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04589845
NCT04613596,A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2/Phase 3,Recruiting,Interventional,Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer,Adagrasib; Adagrasib; Adagrasib; Adagrasib; Pembrolizumab,,Mirati Therapeutics Inc.,,806,2020-12-02,2029-10-31,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Denmark; Finland; France; Georgia; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Norway; Peru; Philippines; Poland; Portugal; Romania; Serbia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04613596
NCT04624555,The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors,,Recruiting,Observational,Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Stage I Colorectal Cancer; Stage II Colorectal Cancer; Stage III Colorectal Cancer,,,Case Comprehensive Cancer Center,,50,2022-10-31,2026-01-30,United States,No,https://clinicaltrials.gov/study/NCT04624555
NCT04677413,"Phase I Trial of Ultra-fractionated Adaptive Radiotherapy, Chemotherapy and Selective Omission of Surgery for Locally Advanced Rectal Cancer",Phase 1,Recruiting,Interventional,Rectal Cancer,Ultrafractionated radiotherapy for rectal cancer,,University of Texas Southwestern Medical Center,,27,2021-06-03,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT04677413
NCT04712877,LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers,,Recruiting,Observational,NSCLC,"ctDNA, tumor NGS",,Lung Cancer Mutation Consortium,Lung Cancer Research Foundation,1000,2022-06-15,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT04712877
NCT04808323,MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer,Phase 1,Recruiting,Interventional,Rectal Adenocarcinoma,Capecitabine; Initial Dose of Radiation before Dose Escalation; Cohort A: Dose Escalation Radiation; Cohort B: Dose Escalation Radiation; Cohort C: Dose Escalation Radiation; FOLFOX,,Medical College of Wisconsin,,22,2021-06-17,2029-01-20,United States,No,https://clinicaltrials.gov/study/NCT04808323
NCT04929223,"A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",Phase 1,Recruiting,Interventional,Metastatic Colorectal Cancer,Inavolisib; Bevacizumab; Cetuximab; Atezolizumab; Tiragolumab; SY-5609; Divarasib; FOLFOX; FOLFIRI; FoundationOne®Liquid CDx,,Hoffmann-La Roche,,542,2021-10-22,2028-11-07,Australia; Canada; Denmark; Germany; Italy; Poland; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04929223
NCT04956640,A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms",LY3537982; Pembrolizumab; Cetuximab; Pemetrexed; Cisplatin; Carboplatin,,Eli Lilly and Company,Merck Sharp & Dohme LLC,540,2021-07-19,2027-04-05,Australia; Canada; France; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04956640
NCT05030038,Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability,,Recruiting,Observational,Breast Cancer,Fecal swab collection; Blood samples,,Wake Forest University Health Sciences,,25,2022-03-29,2026-04-05,United States,No,https://clinicaltrials.gov/study/NCT05030038
NCT05053555,High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies,Not Applicable,Recruiting,Interventional,Liver Malignant Tumors; Cholangiocarcinoma Metastatic; Pancreatic Cancer; Melanoma,high dose rate brachytherapy; high dose rate brachytherapy,,M.D. Anderson Cancer Center,,60,2022-04-24,2027-01-31,United States,No,https://clinicaltrials.gov/study/NCT05053555
NCT05067283,"A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,MK-1084; Pembrolizumab; carboplatin; pemetrexed; cetuximab; oxaliplatin; leucovorin; 5-fluorouracil,,Merck Sharp & Dohme LLC,,830,2021-12-17,2030-02-25,Australia; Canada; Chile; China; Denmark; Israel; Italy; Japan; Lithuania; Malaysia; New Zealand; Panama; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05067283
NCT05074810,A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; KRAS Activating Mutation,avutometinib and sotorasib; avutometinib and sotorasib and defactinib,,"Verastem, Inc.",Amgen,153,2022-04-12,2027-04-05,Belgium; France; Netherlands; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05074810
NCT05118854,A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation,Phase 2,Recruiting,Interventional,Lung Cancer,AMG 510; Cisplatin; Carboplatin; Pemetrexed,,M.D. Anderson Cancer Center,Amgen,27,2022-03-30,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT05118854
NCT05239338,Preserving Fertility After Colorectal Cancer: The PREFACE Study,,Recruiting,Observational,Colorectal Cancer,,,"Andreana Holowatyj, PhD, MSCI",,1000,2021-12-06,2037-12-05,United States,No,https://clinicaltrials.gov/study/NCT05239338
NCT05239546,"Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers",Phase 2,Recruiting,Interventional,Colon Cancer; dMMR Colorectal Cancer,Dostarlimab,,University of Iowa,,25,2023-03-24,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT05239546
NCT05254184,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,12,2022-11-01,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT05254184
NCT05254327,A Randomized Phase 2 Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With and Without BMX-001 as Part of Total Neoadjuvant Therapy in Patients With Newly Diagnosed Locally Advanced Rectal Adenocarcinoma,Phase 2,Recruiting,Interventional,Rectal Cancer,BMX-001,,University of Nebraska,"BioMimetix JV, LLC",118,2022-08-15,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT05254327
NCT05281471,"A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",Phase 3,Recruiting,Interventional,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma,"olvimulogene nanivacirepvec; Platinum chemotherapy: carboplatin (preferred) or cisplatin; Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin; Bevacizumab (or biosimilar)",,Genelux Corporation,GOG Foundation,186,2022-08-31,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT05281471
NCT05309746,Ovarian Tissue Cryopreservation for Fertility Preservation in Post-Pubertal Children Facing a Fertility Threatening Diagnosis or Treatment Regimen,,Recruiting,Observational,Pediatric Cancer,Laparoscopic surgery,,Erin Rowell,,250,2017-11-01,2035-01-05,United States,No,https://clinicaltrials.gov/study/NCT05309746
NCT05321134,Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery,Not Applicable,Recruiting,Interventional,Colo-rectal Cancer; Rectal Prolapse; Colostomy Stoma; Colorectal Disorders,Single port robotic colorectal surgical procedure,,"University of California, Davis","University of California, San Francisco; Yale University; Henry Ford Hospital; University of Massachusetts, Worcester",25,2022-04-28,2028-04-05,United States,No,https://clinicaltrials.gov/study/NCT05321134
NCT05410145,"A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,KRAS P.G12C,D3S-001; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Cetuximab,,"D3 Bio (Wuxi) Co., Ltd",,442,2022-08-03,2027-04-05,Australia; China; France; Germany; Hong Kong; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05410145
NCT05411718,"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome",Phase 2,Recruiting,Interventional,T Cells; Colorectal Cancer; Lynch Syndrome,Naproxen; Aspirin,,M.D. Anderson Cancer Center,National Institutes of Health (NIH); National Cancer Institute (NCI),40,2023-03-21,2026-11-30,United States,No,https://clinicaltrials.gov/study/NCT05411718
NCT05514717,"A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",Phase 1,Recruiting,Interventional,HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Non-Small Cell Lung Cancer; HER2-positive Colorectal Cancer; HER2-positive Tumors; HER2 Low Breast Cancer,XMT-2056,,Mersana Therapeutics,,162,2023-01-24,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT05514717
NCT05552755,"A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)",Phase 1/Phase 2,Recruiting,Interventional,Familial Adenomatous Polyposis,REC-4881; Placebo,,Recursion Pharmaceuticals Inc.,,67,2023-07-10,2026-07-05,United States,No,https://clinicaltrials.gov/study/NCT05552755
NCT05609578,A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced NSCLC; Metastatic Lung Cancer,Adagrasib oral dose of 400 mg twice daily tablets; Pembrolizumab; Chemotherapy: Pemetrexed; Cisplatin/Carboplatin,,Mirati Therapeutics Inc.,,90,2022-11-22,2026-12-01,Brazil; Chile; France; Georgia; Greece; Hungary; Italy; Malaysia; Poland; Serbia; Spain; Switzerland; Thailand; United States,No,https://clinicaltrials.gov/study/NCT05609578
NCT05630794,Phase 1 Trial of ONC201 for Chemoprevention in Colorectal Cancer,Phase 1,Recruiting,Interventional,Colorectal Adenomatous Polyp; Colorectal Carcinoma; Familial Adenomatous Polyposis; Multiple Adenomatous Polyps,Biopsy Procedure; Biospecimen Collection; Colonoscopy; Dordaviprone; Questionnaire Administration; Sigmoidoscopy,,National Cancer Institute (NCI),,36,2025-07-30,2028-03-01,United States,No,https://clinicaltrials.gov/study/NCT05630794
NCT05638295,A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial,Phase 2,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Panitumumab; Sotorasib,,National Cancer Institute (NCI),,105,2024-08-01,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05638295
NCT05684094,Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep Duration and Timing to Reward- and Stress-Related Brain Function,Not Applicable,Recruiting,Interventional,Alcohol Use Disorder,Sleep extension and advance; Regular sleep duration and timing,,University of Oregon,University of Pittsburgh; National Institute on Alcohol Abuse and Alcoholism (NIAAA),90,2023-09-07,2027-02-28,United States,No,https://clinicaltrials.gov/study/NCT05684094
NCT05715255,Adaptive Symptom Self-Management to Reduce Psychological Distress and Improve Symptom Management for Survivors on Immune Checkpoint Inhibitors,Not Applicable,Recruiting,Interventional,Breast Cancer; Colon Cancer; Lung Cancer; Skin Cancer; Rectum Cancer,Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C); Active control comparator,,University of Arizona,National Cancer Institute (NCI),400,2023-05-08,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT05715255
NCT05746897,"A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Ovarian Cancer; Melanoma; Triple Negative Breast Cancer; Colorectal Cancer,NM1F Injection; Pembrolizumab injection,,"Hefei TG ImmunoPharma Co., Ltd.",,38,2023-04-13,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT05746897
NCT05761782,Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education (EDUCATE),,Recruiting,Observational,Cancer Awareness and Prevention Education,Education,,"University of California, Davis",,1500,2023-03-07,2025-03-07,United States,No,https://clinicaltrials.gov/study/NCT05761782
NCT05786924,"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D,S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel,,Institut de Recherches Internationales Servier,,554,2023-04-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT05786924
NCT05789082,"A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer,Divarasib; Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed,,Hoffmann-La Roche,,320,2023-06-20,2032-01-29,Argentina; Australia; Belgium; Brazil; Canada; China; Israel; Italy; Japan; Netherlands; Poland; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05789082
NCT05815173,Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,Sotorasib; Ladarixin,,NYU Langone Health,,40,2023-08-01,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT05815173
NCT05838391,Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma,Not Applicable,Recruiting,Interventional,Anal Squamous Cell Carcinoma,Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery; Mitomycin-C; 5-Fluorouracil; Capecitabine,,Columbia University,Varian Medical Systems,20,2023-05-18,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05838391
NCT05853575,A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung,Adagrasib,,Mirati Therapeutics Inc.,,200,2024-02-16,2026-07-30,Brazil; Croatia; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Serbia; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT05853575
NCT05863195,A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial,Phase 3,Recruiting,Interventional,Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Liver; Stage IV Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma,Bevacizumab; Cetuximab; Computed Tomography; Floxuridine; Fluorouracil; Implantation; Intrahepatic Infusion Procedure; Irinotecan; Leucovorin; Oxaliplatin; Panitumumab; Single Photon Emission Computed Tomography,,ECOG-ACRIN Cancer Research Group,National Cancer Institute (NCI),408,2023-10-19,2034-06-30,United States,No,https://clinicaltrials.gov/study/NCT05863195
NCT05892068,Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance,Phase 2,Recruiting,Interventional,Metastatic Breast Cancer,Tucatinib,,Memorial Sloan Kettering Cancer Center,Pfizer; Seagen Inc.,28,2023-05-09,2028-05-09,United States,No,https://clinicaltrials.gov/study/NCT05892068
NCT05920356,"A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)",Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC),Sotorasib; Pembrolizumab,,Amgen,,750,2023-11-16,2031-06-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Latvia; Malaysia; Mexico; Netherlands; Peru; Poland; Portugal; Romania; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05920356
NCT05961709,The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer,Phase 2,Recruiting,Interventional,Colon Cancer,Cemiplimab,,M.D. Anderson Cancer Center,Regeneron Pharmaceuticals,50,2024-05-20,2028-04-30,United States,No,https://clinicaltrials.gov/study/NCT05961709
NCT05971836,The Molecular Basis of Inherited Reproductive Disorders,,Recruiting,Observational,Hypogonadotropic Hypogonadism; Reproductive Disorder; Kallmann Syndrome; Delayed Puberty,,,"Stephanie B. Seminara, MD",,600,2021-01-21,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT05971836
NCT06026410,"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer); Non Clear Cell Renal Cell Carcinoma (nccRCC),Darlifarnib; Cabozantinib; Adagrasib,,"Kura Oncology, Inc.",Mirati Therapeutics Inc.,300,2023-10-18,2027-04-05,France; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06026410
NCT06040762,"The ""Get Moving Trial"": A Phase I/II RCT of Home-Based (P)Rehabilitation With ExerciseRx in Bladder Cancer and Upper Tract Urothelial Cancer",Not Applicable,Recruiting,Interventional,Bladder Cancer; Urothelial Carcinoma; Upper Tract Urothelial Carcinoma; Renal Pelvis and Ureter Urothelial Carcinoma,Best Practice; Exercise Intervention; App-Based Intervention; App-Based Intervention; Interview; Wearable Activity Tracker; Physical Performance Testing; Questionnaire Administration,,University of Washington,Bladder Cancer Advocacy Network,128,2023-12-19,2026-10-30,United States,No,https://clinicaltrials.gov/study/NCT06040762
NCT06050668,MEND Repair & Recover Clinical Trial,Phase 2,Recruiting,Interventional,Femoral Fracture; Fragility Fracture; Muscle Atrophy,Essential Amino Acid Supplementation,,Michael C Willey,MEND; Slocum Research & Education Foundation,60,2024-06-17,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT06050668
NCT06050707,MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach,Phase 2,Recruiting,Interventional,Anal Squamous Cell Carcinoma,Radiotherapy - Low risk group; Radiotherapy - Standard risk group; Radiotherapy - Intermediate risk group; Radiotherapy - High risk group,,"University Health Network, Toronto",Medical College of Wisconsin,80,2023-09-29,2028-09-01,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06050707
NCT06119581,"SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",LY3537982; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed,,Eli Lilly and Company,,1016,2023-12-21,2029-10-05,Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Mexico; Netherlands; Norway; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06119581
NCT06124339,Interventions to Promote Brain Health Virtual Reality Study,Not Applicable,Recruiting,Interventional,"Aging; Aging Problems; Memory Loss; Memory Impairment; Memory Disorders in Old Age; Memory Disorder, Spatial; Memory Disorders; Mild Cognitive Impairment; Cognitive Decline; Cognitive Change; Cognition Disorders in Old Age",Physical Activity; Cognitive Activity (VR); Physical and Cognitive Activity,,"University of California, San Diego",,150,2023-08-08,2029-02-01,United States,No,https://clinicaltrials.gov/study/NCT06124339
NCT06128551,"Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,Assigned interventions,,"Revolution Medicines, Inc.",,210,2023-11-14,2026-11-30,France; Germany; Italy; Netherlands; Puerto Rico; Spain; United States,No,https://clinicaltrials.gov/study/NCT06128551
NCT06130254,"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Non-small Cell Lung Cancers,Adagrasib; Olaparib,,M.D. Anderson Cancer Center,Mirati Therapeutics Inc.,52,2024-01-30,2030-08-25,United States,No,https://clinicaltrials.gov/study/NCT06130254
NCT06162221,A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,"Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC",RMC-6291; RMC-6236; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; RMC-9805,,"Revolution Medicines, Inc.",,616,2024-01-18,2028-12-05,Australia; Denmark; France; Germany; Greece; Italy; Netherlands; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06162221
NCT06229860,Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia,,Recruiting,Observational,Chronic Myeloid Leukemia; Chronic Phase Chronic Myelogenous Leukemia,Interview,,"University of California, Irvine",,75,2024-01-25,2026-01-05,United States,No,https://clinicaltrials.gov/study/NCT06229860
NCT06244771,"An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumors With KRAS G12C Mutations; Solid Tumor, Adult; Unresectable Solid Tumor; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer; KRAS G12C; Pancreatic Cancer",FMC-376,,Frontier Medicines Corporation,,403,2024-02-12,2028-04-05,Australia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06244771
NCT06248606,Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases,Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; NSCLC; KRAS G12C,Adagrasib; Stereotactic Radiosurgery,,"Ryan Gentzler, MD",Mirati Therapeutics Inc.; University of Virginia,30,2024-08-06,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT06248606
NCT06249282,A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Biopsy; Biospecimen Collection; Carfilzomib; Computed Tomography; Echocardiography; Magnetic Resonance Imaging; Sotorasib,,City of Hope Medical Center,National Cancer Institute (NCI),15,2024-04-24,2026-03-19,United States,No,https://clinicaltrials.gov/study/NCT06249282
NCT06252649,"Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)",Phase 3,Recruiting,Interventional,Metastatic Colorectal Cancer,FOLFIRI Regimen; Sotorasib; Panitumumab; Bevacizumab-awwb,,Amgen,,450,2024-07-17,2031-08-31,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Czechia; Denmark; Estonia; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06252649
NCT06253871,A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations,Phase 1,Recruiting,Interventional,HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer; HER2 + Breast Cancer; Brain Metastases From Solid Tumors; Brain Metastases From HER2 and Breast Cancer; CNS Metastases; HER2-Positive Solid Tumors; NSCLC (Non-small Cell Lung Cancer); HER2-positive Bladder Cancer; HER2-positive Colorectal Cancer; HER2 + Gastric Cancer; HER2-positive Gastroesophageal Cancer,IAM1363,,"Iambic Therapeutics, Inc",,243,2024-03-25,2028-03-05,France; Ireland; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06253871
NCT06265285,"Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",Phase 2,Recruiting,Interventional,Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Metastatic Colorectal Carcinoma; Metastatic Cutaneous Melanoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Cutaneous Melanoma; Unresectable Esophageal Squamous Cell Carcinoma; Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Home Health Encounter; Nivolumab; Patient Monitoring; Questionnaire Administration,,Mayo Clinic,,50,2024-04-30,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06265285
NCT06333951,"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",Phase 1,Recruiting,Interventional,Thoracic Tumors; Non-small Cell Lung Cancer,AMG 193; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Sotorasib,,Amgen,,500,2024-09-17,2031-10-27,Argentina; Australia; Austria; Belgium; Brazil; Canada; China; France; Germany; Greece; Hong Kong; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06333951
NCT06336590,Student Exercise and Sleep Timing Study - Part 2,Not Applicable,Recruiting,Interventional,Sleep; Mood; Stress,Morning Exercise,,"Rutgers, The State University of New Jersey",,62,2024-10-21,2026-12-16,United States,No,https://clinicaltrials.gov/study/NCT06336590
NCT06343402,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma,BBO-8520; Pembrolizumab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,250,2024-05-22,2028-02-05,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06343402
NCT06345729,"A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,MK-1084; Placebo; Pembrolizumab,,Merck Sharp & Dohme LLC,,600,2024-05-24,2031-02-18,Argentina; Australia; Austria; Brazil; Bulgaria; Canada; Chile; China; France; Georgia; Germany; Greece; India; Italy; Japan; Mexico; Netherlands; New Zealand; Philippines; Poland; Romania; South Korea; Spain; Turkey (Türkiye); Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06345729
NCT06357182,A Phase Ib Investigation of the LSD1 Inhibitor Iadademstat (ORY-1001) in Combination With Azacitidine and Venetoclax in Newly Diagnosed AML,Phase 1,Recruiting,Interventional,Acute Myeloid Leukemia; Myelodysplastic Syndrome/Acute Myeloid Leukemia,Azacitidine; Biospecimen Collection; Bone Marrow Biopsy; Echocardiography Test; Iadademstat; Multigated Acquisition Scan; Questionnaire Administration; Venetoclax,,OHSU Knight Cancer Institute,Oregon Health and Science University; Oryzon Genomics S.A.,24,2024-08-22,2026-05-29,United States,No,https://clinicaltrials.gov/study/NCT06357182
NCT06358430,Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD),Phase 1,Recruiting,Interventional,Colorectal Cancer; Minimal Residual Disease,Fludarabine Phosphate; Cyclophosphamide; Cetuximab; TROP2-CAR-NK Cells; Rimiducid (AP1903); Lymphodepleting Chemotherapy,,M.D. Anderson Cancer Center,"Bellicum Pharmaceuticals, Inc.",42,2024-12-02,2029-01-18,United States,No,https://clinicaltrials.gov/study/NCT06358430
NCT06378398,An Early Phase 1 Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy: The Omeprazole and Aspirin Polyp Prevention Study,Early Phase 1,Recruiting,Interventional,Colorectal Neoplasia,Omeprazole; Aspirin,,University of Michigan Rogel Cancer Center,National Cancer Institute (NCI),24,2024-06-14,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT06378398
NCT06403436,"A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Adult Solid Tumor; Adult Disease; Cancer; NSCLC; EGFR; KRAS G12C; Squamous Cell Lung Cancer,TT125-802,,TOLREMO therapeutics AG,,50,2023-11-07,2026-12-05,Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06403436
NCT06412198,"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer; KRAS G12C Mutations,Cetuximab; Cemiplimab; Adagrasib,,M.D. Anderson Cancer Center,,31,2024-08-28,2028-03-01,United States,No,https://clinicaltrials.gov/study/NCT06412198
NCT06447662,A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene,Phase 1,Recruiting,Interventional,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07934040; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin,,Pfizer,,330,2024-06-27,2028-09-09,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06447662
NCT06514794,"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)",Phase 2,Recruiting,Interventional,T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma,WU-CART-007,,"Wugen, Inc.",,125,2025-01-31,2028-12-30,Australia; United States,No,https://clinicaltrials.gov/study/NCT06514794
NCT06582771,A Phase 2 Study of First-line Sotorasib for Patients With Advanced KRAS G12C-mutant Non-small Cell Lung Cancer,Phase 2,Recruiting,Interventional,Non Small Lung Cancer,Sotorasib,,Memorial Sloan Kettering Cancer Center,,39,2024-08-30,2026-08-05,United States,No,https://clinicaltrials.gov/study/NCT06582771
NCT06588686,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People With Idiopathic Pulmonary Fibrosis.",Phase 2,Recruiting,Interventional,Idiopathic Pulmonary Fibrosis (IPF),Buloxibutid; Placebo,,Vicore Pharma AB,Population Services International,360,2024-12-09,2027-06-05,Argentina; Australia; Austria; Belgium; Canada; Germany; Greece; Italy; Mexico; Poland; South Korea; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06588686
NCT06607185,A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,LY4066434.; Cetuximab; Nab paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; Irinotecan; 5Fluorouracil; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab,,Eli Lilly and Company,,750,2024-10-21,2030-01-05,Belgium; China; France; Germany; Italy; Japan; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06607185
NCT06625983,Colorectal Cancer Screening Decision Support Tool in the Primary Care Bundle Questionnaire,Not Applicable,Recruiting,Interventional,Colorectal Cancer Control and Prevention; Colorectal Cancer Screening; Shared Decision Making; Decision Aid,CRC decision tool,,Massachusetts General Hospital,,80000,2024-10-16,2026-08-01,United States,No,https://clinicaltrials.gov/study/NCT06625983
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06710756,"A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive",Phase 1/Phase 2,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Ovarian Cancer; Head and Neck Cancer; Sarcoma; Mesothelioma,[203Pb]Pb-PSV359; [212Pb]Pb-PSV359,,Perspective Therapeutics,,112,2025-04-28,2032-05-28,United States,No,https://clinicaltrials.gov/study/NCT06710756
NCT06720987,"A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations",Phase 1,Recruiting,Interventional,KRAS G12C Mutation; KRAS G12S Mutation; Solid Tumor Malignancies; CRC (Colorectal Cancer),KQB365; Cetuximab,,Kumquat Biosciences Inc.,,128,2025-02-04,2030-06-30,United States,No,https://clinicaltrials.gov/study/NCT06720987
NCT06793215,"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer,Divarasib; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin,,Hoffmann-La Roche,Chugai Pharmaceutical,600,2025-10-24,2030-10-31,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Hungary; Italy; Netherlands; New Zealand; Poland; Portugal; Singapore; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06793215
NCT06804824,"A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,VVD-159642; Sotorasib; Trametinib,,"Vividion Therapeutics, Inc.",,220,2025-02-25,2027-08-01,Australia; United States,No,https://clinicaltrials.gov/study/NCT06804824
NCT06805942,Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis,Not Applicable,Recruiting,Interventional,Plantar Fasciitis of Both Feet,Lipiodol (ethiodized oil) injection,,IR Centers,,10,2025-02-15,2025-09-30,United States,No,https://clinicaltrials.gov/study/NCT06805942
NCT06807619,BrainMet ADePPT (Anticancer Drug Penetration Platform Trial),Phase 1,Recruiting,Interventional,Brain Tumor,Sotorasib,,Memorial Sloan Kettering Cancer Center,Amgen,16,2025-01-29,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT06807619
NCT06874790,"Randomized Controlled Trial of a Choice-driven, Interactive, Storytelling Web-based App to Investigate Mental Health Treatment Initiation Among Symptomatic Latinas",Not Applicable,Recruiting,Interventional,"Mental Health; Anxiety; Depression; Well-Being, Psychological",Catalina; Control webpage,,"University of California, Los Angeles",National Institute of Mental Health (NIMH),700,2025-07-09,2028-11-30,United States,No,https://clinicaltrials.gov/study/NCT06874790
NCT06875310,"A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Adagrasib; Pembrolizumab; Carboplatin; Pemetrexed; Placebo; Cisplatin,,Mirati Therapeutics Inc.,,630,2025-04-24,2032-04-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; France; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Saudi Arabia; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06875310
NCT06876363,"A Phase 1/2 Open-Label, Single-Ascending-Dose Study of EN-374, a Helper-Dependent Adenoviral-Based Gene Therapy, in Participants With X-Linked Chronic Granulomatous Disease",Phase 1/Phase 2,Recruiting,Interventional,X-Linked Chronic Granulomatous Disease,EN-374,,Ensoma,,15,2025-08-05,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06876363
NCT06881784,"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC",Phase 3,Recruiting,Interventional,NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer),daraxonrasib; docetaxel,,"Revolution Medicines, Inc.",,420,2025-05-06,2030-12-01,Australia; Belgium; France; Germany; Hong Kong; Ireland; Italy; Japan; Netherlands; Poland; Puerto Rico; Singapore; South Korea; Spain; Switzerland; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06881784
NCT06890598,"A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Olomorasib; Pembrolizumab; Durvalumab; Placebo,,Eli Lilly and Company,AstraZeneca,700,2025-03-27,2032-02-05,Australia; Austria; Belgium; Brazil; Chile; China; Czechia; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06890598
NCT06896162,PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival,Not Applicable,Recruiting,Interventional,Solid Tumor Malignancies; Metastatic Cancer; Breast Cancer; Colorectal Cancer; Lung Cancer; Bladder Cancer,Expert Review; Blood or tissue samples collection.; The Precision Oncology Navigation,,UNC Lineberger Comprehensive Cancer Center,Eli Lilly and Company,500,2025-06-27,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT06896162
NCT06914726,Randomized Trial to Improve Care of Patients With Hereditary Cancer Syndromes,Not Applicable,Enrolling by invitation,Interventional,"Hereditary Breast/Ovarian Cancer (brca1, brca2); Lynch Syndrome; Genetic Variation; HBOC Syndrome; Hereditary Cancer Syndromes",Patient Centered Clinical Decision Support (PC-CDS),,HealthPartners Institute,National Cancer Institute (NCI),2488,2025-07-09,2029-03-31,United States,No,https://clinicaltrials.gov/study/NCT06914726
NCT06917079,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers",Phase 1,Recruiting,Interventional,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",BBO-11818; Pembrolizumab; Platinum chemotherapy (cisplatin or carboplatin); Pemetrexed; Cetuximab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,287,2025-03-31,2029-09-05,United States,No,https://clinicaltrials.gov/study/NCT06917079
NCT06964633,The Ku Ola Project,Not Applicable,Not yet recruiting,Interventional,Health Promotion; Health,Kūkākūkā Discussion Sessions,,University of Hawaii,,600,2025-11-01,2026-05-31,United States,No,https://clinicaltrials.gov/study/NCT06964633
NCT06972667,Interventions to Decrease Cancer Information Avoidance,Not Applicable,Not yet recruiting,Interventional,Health Information Avoidance,Video to promote colonoscopy; Video to promote screening for colorectal cancer with home tests,,State University of New York at Buffalo,National Cancer Institute (NCI),1500,2025-10-05,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT06972667
